Xeris Biopharma Holdings (XERS) FCF Margin (2020 - 2026)
Xeris Biopharma Holdings (XERS) posted FCF Margin of 11.87% for Q1 2026, down 49.17% on a QoQ basis from 23.36% in Q4 2025, and up 2856.0% year-over-year from 0.4% in Q1 2025.
Xeris Biopharma Holdings (XERS) FCF Margin (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings' FCF Margin history runs 7 years deep, the most recent figure standing at 11.87% for Q1 2026.
- Quarterly FCF Margin rose 2856.0% year-over-year to 11.87% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 15.41% (up 2741.0% YoY) and the FY2025 annual result came in at 9.81%, up 2802.0% from the prior year.
- FCF Margin was 11.87% for Q1 2026 at Xeris Biopharma Holdings, down from 23.36% in the prior quarter.
- Across five years, FCF Margin topped out at 24.78% in Q3 2025 and bottomed at 219.31% in Q1 2022.
- A 5-year average of 33.96% and a median of 21.53% in 2024 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2022 — FCF Margin jumped 14471 bps — and 2024, when it tumbled 1354 bps.
- Xeris Biopharma Holdings' FCF Margin stood at 48.63% in 2022, then jumped by 135 bps to 16.83% in 2023, then slumped by 80 bps to 3.29% in 2024, then soared by 611 bps to 23.36% in 2025, then plunged by 49 bps to 11.87% in 2026.
- Business Quant data shows XERS's FCF Margin at 11.87% in Q1 2026, 23.36% in Q4 2025, and 24.78% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -5.22% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 12.86% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -5.35% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 46.54% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 9.93% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 17.73% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -2.77% |
| 10 | Xeris Biopharma Holdings | 1.43 Bn | 1.32 Bn | 72.55 Mn | 11.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.87% |
| Dec 31, 2025 | 23.36% |
| Sep 30, 2025 | 24.78% |
| Jun 30, 2025 | 0.25% |
| Mar 31, 2025 | -16.69% |
| Dec 31, 2024 | 3.29% |
| Sep 30, 2024 | -15.30% |
| Jun 30, 2024 | -21.53% |
| Mar 31, 2024 | -49.96% |
| Dec 31, 2023 | 16.83% |
| Sep 30, 2023 | -30.24% |
| Jun 30, 2023 | -36.16% |
| Mar 31, 2023 | -78.74% |
| Dec 31, 2022 | -48.63% |
| Sep 30, 2022 | -59.73% |
| Jun 30, 2022 | -81.44% |
| Mar 31, 2022 | -219.31% |
| Dec 31, 2021 | -135.69% |
| Sep 30, 2021 | -204.44% |
| Jun 30, 2021 | -224.81% |